Nanocellulose-based Smart Delivery Systems for Personalized Medicine
Legal Citation
Summary of the Inventive Concept
A next-generation nanocellulose-derived hydrogel drug delivery system that integrates machine learning, 3D printing, and wearable sensors to provide adaptive, personalized, and real-time controlled release of therapeutic agents.
Background and Problem Solved
The original patent's limitations in terms of fixed release kinetics, lack of real-time monitoring, and limited adaptability to patient needs are addressed by the new inventive concept, which envisions a paradigm shift towards smart, adaptive, and personalized drug delivery systems.
Detailed Description of the Inventive Concept
The new inventive concept comprises a range of nanocellulose-based implantable devices, hydrogels, and biohybrid materials that leverage machine learning algorithms, 3D printing, and wearable sensors to create personalized, adaptive, and real-time controlled release of therapeutic agents. The devices and materials are designed for minimally invasive implantation, remote triggering, and on-demand release, ensuring enhanced bioavailability, reduced immune response, and improved treatment outcomes.
Novelty and Inventive Step
The new claims introduce a novel combination of machine learning, 3D printing, and wearable sensors to create adaptive, personalized, and real-time controlled release of therapeutic agents, which is not obvious from the original patent and represents a significant inventive step.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept could include the use of different nanocellulose sources, variations in 3D printing techniques, and integration with other wearable devices or sensors to expand the scope of applications and improve treatment outcomes.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the personalized medicine market, with applications in chronic disease management, cancer treatment, and gene therapy, among others. The target industries include pharmaceuticals, biotechnology, and medical devices.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K47/38 |
| A | A61 | A61K47/40 |
| A | A61 | A61L27/20 |
| A | A61 | A61L27/52 |
| B | B82 | B82Y5/00 |
| B | B82 | B82Y30/00 |
| B | B82 | B82Y40/00 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Nanomedicine, drug delivery systems, biomaterials, with a focus on nanocellulose-based hydrogel technologies for controlled pharmaceutical delivery
Person of Ordinary Skill (PHOSITA) Profile
A researcher with advanced degrees in materials science, bioengineering, or pharmaceutical sciences, possessing expertise in polymer chemistry, drug delivery mechanisms, and nanotechnology fabrication techniques
Obviousness Rationale
A PHOSITA would recognize that the PTD's integration of machine learning, 3D printing, and wearable sensor technologies represents a predictable extension of existing nanocellulose drug delivery research. The core nanocellulose hydrogel technology remains fundamentally consistent with the source patent, with the proposed variations representing incremental improvements using known interdisciplinary techniques. The combination of existing drug delivery principles with emerging digital health technologies would be considered an obvious approach for enhancing pharmaceutical treatment strategies.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,632 |
|---|---|
| Title | Nanocellulose as an embedding matrix and applications thereof |
| Assignee(s) | INNOSENSE LLC |